Galectin Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GALT research report →
Companygalectintherapeutics.com
Galectin Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- CEO
- Joel Lewis
- IPO
- 2002
- Employees
- 15
- HQ
- Norcross, GA, US
Price Chart
Valuation
- Market Cap
- $138.30M
- P/E
- -5.26
- P/S
- 0.00
- P/B
- -1.06
- EV/EBITDA
- -13.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 21.05%
- ROIC
- -192.30%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-30,836,000 · 34.46%
- EPS
- $-0.48 · 36.84%
- Op Income
- $-20,085,000
- FCF YoY
- 42.84%
Performance & Tape
- 52W High
- $7.13
- 52W Low
- $1.22
- 50D MA
- $2.51
- 200D MA
- $3.89
- Beta
- 0.45
- Avg Volume
- 339.55K
Get TickerSpark's AI analysis on GALT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 26 | Brem Henry | other | 60,000 |
| Mar 12, 26 | Brem Henry | other | 0 |
| Feb 6, 26 | ELDRED KARY | buy | 300 |
| Jan 16, 26 | LEWIS JOEL | other | 91,000 |
| Jan 16, 26 | CARSON BENJAMIN SR | other | 60,000 |
| Jan 16, 26 | Zordani Richard A. Jr. | other | 60,000 |
| Jan 16, 26 | Jamil Khurram | other | 100,000 |
| Jan 16, 26 | Jamil Khurram | other | 65,000 |
| Jan 16, 26 | FREEMAN KEVIN D | other | 60,000 |
| Jan 16, 26 | ELDRED KARY | other | 60,000 |
Our GALT Coverage
We haven't published any research on GALT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GALT Report →